迈瑞医疗(300760) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 6,943,108,994, representing a 20.10% increase compared to CNY 5,781,049,735 in the same period last year[1] - Net profit attributable to shareholders for Q1 2022 was CNY 2,105,071,901, up 22.74% from CNY 1,715,036,341 in the previous year[1] - The net profit excluding non-recurring gains and losses was CNY 2,072,184,897, reflecting a 22.20% increase from CNY 1,695,726,614 year-on-year[1] - The basic earnings per share for Q1 2022 was CNY 1.7375, a 23.17% increase from CNY 1.4107 in the same quarter last year[1] - The net profit attributable to shareholders in Q1 2022 was CNY 2,105.07 million, up 22.74% compared to the same period last year, indicating an improvement in net profit margin due to scale effects[9] - The net profit for the first quarter of 2022 was CNY 2,106,972,682, representing an increase of 22.8% compared to CNY 1,715,532,489 in the same period last year[18] - The total profit for the quarter was CNY 2,405,706,107, compared to CNY 1,902,661,830, indicating a year-over-year increase of 26.5%[18] Cash Flow and Assets - The net cash flow from operating activities decreased by 21.68% to CNY 869,750,366 from CNY 1,110,538,731 in the previous year[1] - The cash flow from operating activities was CNY 869,750,366, down from CNY 1,110,538,731, showing a decrease of 21.7% year-over-year[21] - The cash and cash equivalents at the end of the period were CNY 14,669,373,787, down from CNY 16,509,268,253, a decrease of 11.1%[21] - The company incurred a net cash outflow from investing activities of CNY 294,278,032, compared to a net outflow of CNY 243,082,947 in the previous year[21] - Total assets at the end of Q1 2022 were CNY 38,336,461,111, a slight increase of 0.61% from CNY 38,103,022,990 at the end of the previous year[1] - The company's total liabilities decreased to CNY 10,286,737,317 from CNY 11,134,976,999, indicating improved financial health[15] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.01% to CNY 28,032,580,241 from CNY 26,952,803,219 at the end of the previous year[1] - The total number of ordinary shareholders at the end of the reporting period was 64,265[3] - The company completed a share repurchase plan, acquiring 3,249,872 shares at an average price of CNY 307.60 per share, totaling approximately CNY 999.94 million[12] - The total number of shares after the second repurchase decreased from 1,215,691,266 to 1,212,441,394 shares[12] Research and Development - R&D investment in Q1 2022 was CNY 742 million, accounting for 10.69% of operating revenue, with a focus on high-end product innovation[10] - The company launched several innovative products in Q1 2022, including the BC-700 series blood cell analyzer and the TEX20 high-end ultrasound system[10] - Research and development expenses rose to CNY 703,945,494, compared to CNY 587,917,833, indicating a focus on innovation and product development[17] Market and Future Outlook - The international market has shown significant recovery, particularly in North America, benefiting from breakthroughs with high-end medical networks[9] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[17] - The company plans to continue strengthening product R&D, marketing expansion, and localization efforts to capture opportunities in the post-pandemic era[9] Operational Performance - Operating costs for the quarter were CNY 4,630,030,820, up from CNY 3,978,391,572, reflecting a significant increase in operational expenses[17] - Accounts receivable increased to CNY 2,210,780,608, up from CNY 1,658,675,548, suggesting growth in sales and potential future revenue[14] - Inventory levels rose to CNY 3,886,858,084, compared to CNY 3,565,329,699, indicating increased production or stockpiling of products[14] - The operating profit for the first quarter was CNY 2,401,535,649, an increase from CNY 1,905,201,820, representing a growth of 26%[18] Comprehensive Income - The company reported a total comprehensive income of CNY 2,025,451,984, compared to CNY 1,723,292,602 in the same quarter last year, marking an increase of 17.6%[19] - The company reported a decrease in other comprehensive income, with a net amount of CNY -81,520,698 compared to CNY 7,760,113 in the previous year[18]